The June 2016 NAIT newsletter is available – 1200.120 is open for accrual!
The June 2016 NAIT newsletter can be found HERE.
The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.
1200.120 – Open for accrual! Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology.
HELPING FAMILIES NAVIGATE: To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.
SickKids is one of only two centres in Canada offering MIBG therapy.
For more information, please visit